Loading data for THNR — first visit, this takes a few seconds.
Amplify Weight Loss Drug & Treatment ETF (THNR)
NYSEArca: THNR
· 即時價格 · USD
26.70
-0.84 (-3.05%)
收盤價： Sep 01, 2026, 3:10 PM
Amplify Weight Loss Drug & Treatment ETF（THNR）ETF 價格、持股與分析
| 買價 | 27.5 |
| 市值 | 不適用 |
| AUM | 5.07M |
| 資產淨值 | 27.49 |
| 貝他值 | 0 |
| EPS (ttm) | 不適用 |
| 本益比（ttm） | 19.33 |
| 分享出去 | 不適用 |
| 成立日期 | May 20, 2024 |
| 賣價 | 0 |
| 成交量 | 9,624 |
| 20 日平均成交量 | 2,193 |
| 開盤價 | 27.80 |
| 前收盤價 | 27.54 |
| 當日區間 | 27.41 - 27.55 |
| 52 週範圍 | 22.63 - 27.80 |
| 持股 | 不適用 |
| 總費用率 | 0.59% |
關於 THNR
The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is non-diversified.
十大持股 61.60 資產%
| 名稱 | 代號 | 重量 |
|---|---|---|
| Novo Nordisk As Adr | NVO | 9.7% |
| Eli Lilly And Co | LLY | 8.92% |
| Regeneron Pharmaceut... | REGN | 6.03% |
| Cspc Pharmaceutical ... | 1093.HK | 5.52% |
| Arrowhead Pharmaceut... | ARWR | 5.34% |
| Innovent Biologics I... | 1801.HK | 5.34% |
| Amgen Inc | AMGN | 5.25% |
| Abbvie Inc | ABBV | 5.24% |
| Roche Holding Ag Ord... | ROP.SW | 5.2% |
| Merck & Co Inc | MRK | 5.06% |
第 1 頁，共 2 頁